G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT
Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning
About this trial
This is an interventional treatment trial for Myelodysplastic Syndrome
Eligibility Criteria
Inclusion Criteria:
- RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo-HSCT
- 14-65 years
Exclusion Criteria:
- Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)
- Patients with any conditions not suitable for the trial (investigators' decision)
Sites / Locations
- Department of Hematology,Nanfang Hospital, Southern Medical University
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
G-CSF + Decitabine + BUCY
BUCY
For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo-HSCT ,Granulocyte Colony-Stimulating Factor(G-CSF)+Decitabine+BUCY conditioning regimen was G-CSF 5-10ug/kg/day on days -17 and -10 (when white blood cell is more than 20G/L, stop using G-CSF);Decitabine 20mg/m2/day on days -14 and -10; Busulfan (BU) 3.2 mg/kg/day on days -7 and -4;Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo-HSCT ,BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4;Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.